Abstract：ObjectiveTo explore the clinical efficacy of Atorvastatin in the treatment of acute respiratory distress syndrome(ARDS).MethodsAltogether 50 patients with ARDS who were treated in intensive care unit(ICU)of our hospital from January 2015 to December 2016 were selected as subjects and randomly divided into the control group(n=25)and the observation group (n=25)according to the random number table method.The control group was given mechanical ventilation to adjust the positive pressure of the terminal respiration and the oxygen concentration,the control group was also given etiological treatment of primary diseases and anti-infective treatment based on reasonable application.On the basis of the control group,the observation group was fed with Atorvastatin Tablets by the nose at night,40 mg per day,and was treated for 28 days.The levels of C-reactive protein,complement C3,complement C4,CD4+/CD8+,cholesterol,triacylglycerol,low-density lipoprotein and high-density lipoprotein were compared and observed.And the time of mechanical ventilation,stay in intensive care unit(ICU)and length of stay in hospital were compared between two groups.ResultsAfter treatment,the C-reactive protein level of the observation group was lower than that of the control group (P＜0.05).No statistically significant difference was seen between two groups in the complement C3,C4 and CD4+/CD8+(P＞0.05).The cholesterol,triacylglycerol,low-density lipoprotein and high-density lipoprotein of the observation group were lower than those of the control group,with statistically significant difference (P＜0.05).After treatment,the time of mechanical ventilation,stay in intensive care unit(ICU)and length of stay in hospital of the observation group were all shorter than those of the control group,with statistically significant difference (P＜0.05).ConclusionAtorvastatin can reduce the inflammatory reaction of ARDS patients and improve patients′immunity and prognosis,which has certain clinical application value.
Heart N.Randomized，placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury[J].Am J Respir Crit Care Med，2011，184（5）：561-568.
[2]
Gao FS，Perkins GD，Gates S，et al.Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome （BALTI-2）：a multicentre，randomised controlles trial[J].Lancet，2012，379（9812）：229-235.
Craig TR，Duffy MJ，Shyamsundar M，et al.A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury （The HARP Study）[J].Am J Respir Crit Care Med，2011，183（5）：620-626.
[6]
Craig TR，Duffy MJ，Shyamsundar M，et al.A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury （The HARP Study）[J].Am J Respir Crit Care Med，2011，183（5）：620-626.
[7]
Husari AW，Khayat A，Awdeh H，et al.Activated protein C attenuates acute lung injury and apoptosis in a hyperoxic animal model[J].Shock，2010，33（5）：467-472.
京公网安备 11010502046607号